Inhibitors are a serious complication of hemophilia caused by an immune response to clotting factor concentrates. Treatment of inhibitors is one of the biggest challenges in hemophilia care today. This primer explains our current understanding of how and why inhibitors form, reviews the established approaches to managing inhibitors, and looks ahead to some potential future developments in the field.
The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in up to 40% of people with severe hemophilia A
In the Monday morning session entitled Inhibitors: Clinical Aspects, Jan Astermark described the different diagnostic assays laboratories can carry out